Author:
Fuentes-García Ruth,Naranjo Lizbeth,Caro-Vega Yanink
Publisher
Springer International Publishing
Reference20 articles.
1. Calmy, A., Tovar Sanchez, T., Kouanfack, C., et al.: Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): Week 96 results from a two-group, multicenter, randomized, open label, phase 3 non-inferiority trial in Cameroon. Lancet HIV 7(10), e677–e687 (2020)
2. Caro-Vega, Y., Belaunzarán-Zamudio, P.F., Crabtree-Ramírez, B.E., et al.: Durability of efavirenz compared with boosted protease inhibitor-based regimens in antiretroviral-naïve patients in the Caribbean and Central and South America. Open Forum Infect. Dis. 5(3), ofy004 (2018)
3. Wohl, D.A., Yazdanpanah, Y., Baumgarten, A., et al.: Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomized, double-blind, multicenter, phase 3, non-inferiority trial. Lancet HIV 6(6), e355–e363 (2019)
4. Castillo-Mancilla, J.R., Brown, T.T., Erlandson, K.M., et al.: Suboptimal adherence to combination antiretroviral therapy is associated with higher levels of inflammation despite HIV suppression. Clin. Infect. Dis.: Offic. Publ. Infect. Dis. Soc. Am. 63(12), 1661–1667 (2016)
5. Castillo-Mancilla, J.R., Brown, T.T., Palella, F.J.J., et al.: Partial normalization of biomarkers of inflammation and immune activation among virally suppressed men with HIV infection and high ART adherence. Open Forum Infect. Dis. 7(4), ofaa099 (2020)